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Since the 1960s simple inexpensive cold lactated Ringers with additives has been used for short-term cold preservation 
of kidneys from living donors. We performed 266 living donor kidney transplantations from January 22, 2003 to 
October 30, 2006. Donor allografts were recovered laparoscopically and flushed with cold heparin, lactated Ringer's and 
procaine (HeLP) solution. Warm and cold ischemic times were typically <45 min and <90 min, respectively. The mean 
follow up was 21.6± 12.2 months. There was no delayed graft function. Actuarial I-year patient and graft survival were 
98.6% and 98.1 %, respectively. The creatinine at 1 year was 1.46±0.51 mgldL. The cumulative incidences of acute 
cellular rejection at 6,12,18, and 24 months were 3.0%, 7.1 %,10.2%, and 11.7%. There were no identifIable side effects 
attributed to the HeLP solution. This study documents the effectiveness of cold HeLP as a flushing and short-term 
preservation fluid for living donor kidney transplantation with excellent results and signifIcant cost benefit because of 
its low cost. 
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(Transplantation 2007;83: 1134-1136) 
The shortage of organs remains an ongoing problem in 
transplantation. Another important issue in transplanta-
tion is the ever-increasing medical expenses associated with 
it. Although it is important to reduce costs, it is important 
that outcomes are not affected. One potential area of cost 
savings is the use of a simple preservation fluid in living donor 
kidney transplantation because of the associated short warm 
and cold ischemia times. 
Lactated Ringer's (LR) was one of the first preservation 
fluids to be used in transplant surgery, but was replaced by 
Collins, ViaSpan (Belzer UW), Custodiol HTK, and others. 
These solutions were developed with the goal of reducing 
organ damage and ischemia/reperfusion injury, including 
cellular swelling, oxygen-free radical injury, and cell mem-
brane destruction. For example, lactobionate and gluconate 
are impermeable anions that prevent cellular edema and act 
as buffers to maintain the pH, adenosine provides adenosine 
tri-phosphate (ATP) as a source of energy for cell metabo-
lism, steroids and other substances act to stabilize lysosomal 
membranes, and lidocaine prevents postischemia vasocon-
striction and escalation of anaerobic respiration in the cells. 
On the other hand, with the short ischemia times in living-
donor kidney transplantation, we had had a 19-year experi-
ence with the use of a simple and less expensive solution, LR, 
with two inexpensive additives, heparin and procaine (1). We 
looked at our recent experience with this HeLP (10,000 U 
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heparin, 1 L oflactated Ringer's, and 100 mg procaine) solu-
tion, in living donor kidney transplantation. 
PATIENTS AND METHODS 
Between January 22,2003 and October 30, 2006, a total 
of266 consecutive laparoscopic (2) live donor n~phrectomies 
resulting in 266 living donor kidney-only trtmsplantations 
were performed at the University of Pittsburgh Medical Cen-
ter Starzl Transplantation Institute (UPMC STI) (3). All do-
nors were given heparin 3,000 units intravenously at least 3 
min prior to clamping of the renal vessels. All kidneys were 
immediately placed into an iced saline bath and flushed with 
cold (SoC) HeLP solution until the effluent was clear. All re-
cipients received pretreatment with a single dose of 30 mg 
of intravenous alemtuzumab and posttransplant tacrolimus 
monotherapy. 
Modification in the timing and dosage of conventional 
immunosuppression in this regimen was submitted to the 
University of Pittsburgh Institutional Review Board, which 
judged the changes to be within the boundaries of historically 
based standard treatment. The use of HeLP in living donor 
kidney transplantation has been a standard of care practice at 
UPMC STI since 1987. The treatment protocols were re-
viewed by the University of Pittsburgh Medical Center Com-
mittee on Innovative Practices and by the Pharmacy and 
Therapeutics Practices Committee, with approval by both. 
All patients provided informed consent. 
RESULTS 
All kidneys functioned immediately; there were no 
cases of slow graft function, delayed graft function (DGF), or 
primary nonfunction. There was no vascular thrombosis. The 
mean human leukocyte antigen mismatch was 3.3 ± 1.6. Ac-
tuarial I-year patient and graft survival were 98.6% and 
98.1 %, respectively, and compared favorably with Organ 
Procurement and Transplantation Network/Scientific Regis-
try of Transplant Recipients patient and graft survival rates of 
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FIGURE 1. (A) Postdonation, 
pretransplant biopsy: normal pre-
perfusion renal tubules flushed with 
HeLP solution. (B) Posttransplant bi-
opsy: normal postreperfusion renal 
tubules without acute tubular necro-
sis. (C) Postdonation, pretransplant 
biopsy: normal prereperfusi.on re-
nal glomeruli flushed with HeLP s0-
lution. (D) Posttransplant biopsy: 
normal postreperfusion renal 
glomeruli. 
97.9% and 95.1%, respectively (4). The cumulative inci-
dences of acute cellular rejection (ACR) at 1,2,3,4,6, 12, 18, 
and 24 months were 1.9%, 1.9%, 2.3%, 2.6%, 3.0%, 7.1 %, 
10.2%, and 11.7%, respectively. Most (>80%) episodes of 
ACR were Banff 1a or b and were sensitive to steroid pulses for 
treatment of rejection. 
The mean donor hospital stay was 2.9:1:: 0.8 days and the 
mean recipient length of stay was 5.4:1::2.6 days. There were 
no allergic or any side effects (including heparin-induced 
thrombocytopenia and arrhythmias) attributed to HelP. 
Despite the complexity of the recipient population, which 
included 37 retransplants, 4 human immunodeficiency 
virus-positive recipients, and 24 pediatric recipients, we 
achieved low ACR rates and excellent patient and graft sur-
vivals rates. Furthermore, good graft function was also ob-
served, with a mean serum creatinine at 1 year and at mean 
21.6 months follow-up of 1.46:1::0.51 mg/dl and 1.49:1::0.71 
mg/dL, respectively. As shown in Figure 1, there was minimal 
inflammation in the tubules and glomeruli in the kidneys that 
were flushed and preserved with HelP. 
DISCUSSION 
Cold ischemia is known to be associated with less allo-
graft injury than warm ischemia (5). One unique character-
istic in living donor renal transplantation is a short warm 
(typically <5 min for laparoscopic kidney extraction [this 
series includes up to five renal arteries 1 and about 30 to 45 
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min for the vascular anastomoses) and cold ischemia time 
(typically < 1 hr). These short warm and cold ischemia times 
allowed us to continue the use of the cold (5°C) HeLP solu-
tion as a flushing and short-term preservation fluid with ex-
cellent results. Despite its long use at UPMC STI and at other 
transplant centers, this is the first report of using a rather 
simple cold preservation fluid (heparin and procaine in LR) 
that is both safe and cost-effective in living donor kidney 
transplantation. 
Under nonischemic and nonhypothermic condi-
tions, intracellular sodium is extruded through the sodium-
potassium adenosine triphosphatase (6). Hypothermia and 
ischemia render this pump virtually nonfunctional. Intracel-
lular sodium levels rise during ischemia, and are prevented by 
the sodium channel blocker procaine. Procaine also inhibits 
the activation of the enzyme phospholipase A, which has de-
structive properties on the cell membrane. This mechanism 
may be involved in the antiarrhythmic action of the drug and 
constitutes a potential for metabolic postischemic protection 
(7). Procaine is an ester anesthetic, metabolized in the plasma 
by the enzyme acetylcholinesterase (AChE). It is stable when 
freshly prepared and used immediately in slightly acidic cold 
HelP solution (pH of heparin in LR is 6.28, and pH of pro-
caine in heparin and lR is 6.22). AChE is a marker of red 
blood cell (RBC) membrane integrity, and determines RBC 
aggregation and deformability. During blood bank storage, 
improved preservation of RBCs is associated with a decrease 
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in AChE. Because procaine is an ester, it is hydrolyzed in-
stantly on contact with blood by serum esterases. When ad-
ministered in cold preservation fluid, the effects last through 
the ischemia period, but at organ reperfusion, it is washed out 
and metabolized rapidly (8). We used 0.1 giL (9) of procaine 
because higher doses (e.g., 1 giL) have shown to be toxic (10). 
The patient cost for 1 L of HeLP is $2.83 (lO,OOO U 
heparin=$0.50, LR=$0.83, 100 mgprocaine=$1.50). This is 
a significant cost reduction compared to the vendors' charges 
to the hospital of Viaspan ($282/L) and Custodiol HTK 
($l72/L). The use ofLR with heparin and procaine is as effec-
tive as the more expensive Viaspan or Custodiol HTK solu-
tions in living donor kidney transplantation because of the 
inherent short cold and warm ischemia times, thereby saving 
about $280 with ViaSpan or $170 with Custodiol HTK per 
patient, and potentially $1,200,000 to $1,800,000 (6,563liv-
ing donor kidney transplants were done in 2005 [4]) across 
the United States. Cold HeLP solution is obviously not a rea-
sonable preservation solution for deceased donor kidney 
transplantation, but can be used safely for living donor kidney 
transplantation. It may also not be optimal in smaller trans-
plant centers with long cold ischemia times, particularly in 
programs that do not have the benefit of two simultaneous 
operating rooms and may need to do the recipient after the 
living donor, thus entailing significantly longer cold ischemia 
times. The longest cold ischemia time in this series, however, 
was 5 hours. 
, !. 
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